At just 52 years old, a woman has been diagnosed with Stage 4 lung cancer. A non-smoker who had worked full-time since age 22 ...

A 14-gene assay predicts chemotherapy benefit in early-stage non-small-cell lung cancer, improving 24-month disease-free ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

David Roach has shared a shocking health update. The Junkyard frontman and his fiancée, Jennifer, took to Instagram on ...